The annexin A5 protective shield model revisited: inherited carriage of the M2/ANXA5 haplotype in placenta as a predisposing factor for the development of obstetric antiphospholipid antibodies

Abstract

This concise review summarizes the role of reduced ANXA5 expression through carriage of the M2/ANXA5 haplotype as a predisposing factor for various thrombophilia related obstetric complications. A revised ANXA5 ‘protective shield’ model is emphasized, where decreased coverage resulting of M2 carriage at placental villi could lead directly to the observed pathology and on the other hand through exposing of antiphospholipid antigenic determinants, to the development of antiphospholipid antibodies (aPL). The aPL then can further disrupt the ANXA5 protective shield. Available and prospective evidence for this revised model is discussed. Conclusions are made about the diagnostic implications of M2 carriage and possible therapeutic strategies with anticoagulants, proven successful in obstetric antiphospholipid syndrome (APS) treatment.

Keywords

annexin A5 ANXA5 aPL aPS M2/ANXA5 obstetric APS

Get full access to this article

View all access options for this article.

References

Gerke

Creutz

Moss

. Annexins: linking Ca2⁺ signalling to membrane dynamics. Nat Rev Mol Cel Biol 2005; 6: 449–461.

Thiagarajan

Tait

. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990; 265: 17420–17423.

Romisch

Seiffge

Reiner

Paques

Heimburger

. In-vivo antithrombotic potency of placenta protein 4 (annexin V). Thromb Res 1991; 61: 93–104.

Rand

Guller

. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171: 1566–1572.

Bouter

Gounou

Bérat

. Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair. Nat Commun 2011; 2: 270–270.

Rand

. Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost 1999; 82: 649–655.

Bogdanova

Horst

Chlystun

. A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss. Hum Mol Genet 2007; 16: 573–578.

Tiscia

Colaizzo

Chinni

. Haplotype M2 in the annexin A5 (ANXA5) gene and the occurrence of obstetric complications. Thromb Haemost 2009; 102: 309–313.

Chinni

Tiscia

Colaizzo

Vergura

Margaglione

Grandone

. Annexin V expression in human placenta is influenced by the carriage of the common haplotype M2. Fertil Steril 2010; 91: 940–942.

10.

Grandone

Tiscia

Colaizzo

. Role of the M2 haplotype within the annexin A5 gene in the occurrence of pregnancy-related venous thromboembolism. Am J Obstet Gynecol 2010; 203: 461.e1-5–461.e1-5.

11.

Miyamura

Nishizawa

Ota

. Polymorphisms in the annexin A5 gene promoter in Japanese women with recurrent pregnancy loss. Mol Hum Reprod 2011; 17: 447–452.

12.

Shu

Sugimura

Kanayama

Kobayashi

Terao

. Immunohistochemical study of annexin V expression in placentae of preeclampsia. Gynecol Obstet Invest 2000; 49: 17–23.

13.

Sifakis

Soufla

Koukoura

. Decreased annexin A5 mRNA placental expression in pregnancies complicated by fetal growth restriction. Thromb Res 2010; 125: 326–331.

14.

Rand

Arslan

. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol 2006; 194: 182–188.

15.

Markoff

Gerdes

Feldner

Bogdanova

Gerke

Grandone

. Reduced allele specific annexin A5 mRNA levels in placentas carrying the M2/ANXA5 allele. Placenta 2010; 31: 937–940.

16.

Ueki H, Nishimura Y, Rieanrakwong D, et al. Maternal annexin A5 is required for preventing placental thrombosis and fetal loss. Poster at the: 6th International Conference on Annexins, Barcelona, 28–31 August 2011.